Health
AstraZeneca Expands Research Partnerships
AstraZeneca is investing $2 billion in Summit Therapeutics to test a new PD-1/VEGF bispecific ivonescimab alongside its own antibody-drug conjugates.
Coverage timeline — 1 article
STAT News
AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
2026-09-29 13:52 UTC